Latest Property Portfolio News

Page 5 of 22
Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.
Ada Torres
Ada Torres
17 Dec 2025
Region Group reports a $129 million uplift in its investment property portfolio valuation as of December 2025, alongside improved net tangible assets and stable gearing levels.
Eva Park
Eva Park
16 Dec 2025
An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.
Ada Torres
Ada Torres
12 Dec 2025
Charter Hall Retail REIT has announced a quarterly unfranked dividend of AUD 0.064 per unit, payable in February 2026, maintaining steady income for investors amid a stable retail property market.
Victor Sage
Victor Sage
11 Dec 2025
EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.
Ada Torres
Ada Torres
11 Dec 2025
ChemX Materials Limited has emerged from voluntary administration following a Deed of Company Arrangement, while securing a significant Japanese patent for its HiPurA® High Purity Alumina process.
Maxwell Dee
Maxwell Dee
9 Dec 2025
Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.
Ada Torres
Ada Torres
27 Nov 2025
Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.
Ada Torres
Ada Torres
26 Nov 2025
Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.
Logan Eniac
Logan Eniac
26 Nov 2025
Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.
Ada Torres
Ada Torres
26 Nov 2025
Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.
Ada Torres
Ada Torres
25 Nov 2025
Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.
Ada Torres
Ada Torres
21 Nov 2025